Angiogenesis and vascular targeting: Relevance for hyperthermia

References

• Brem S, Brem H, Folkman J, Finkelstein D, Patz A. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 1976; 36: 2807–2812
   PubMed Web of Science ®Google Scholar
• Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue?. Cancer Res 1986; 46: 467–473
   PubMed Web of Science ®Google Scholar
• Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: A dynamic theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999; 59: 4770–4775
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Revs Cancer 2003; 3: 401–410
   PubMed Web of Science ®Google Scholar
• Denekamp J, Hill S. Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol 1991; Suppl.20: 103–112
   Web of Science ®Google Scholar
• Horsman MR. Tissue physiology and the response to heat. Int J Hyperthermia 2006; 22: 197–203
   PubMed Web of Science ®Google Scholar
• Jain RK, Grantham FH, Gullino PM. Blood flow and heat transfer in Walker 256 mammary carcinoma. J Natl Cancer Inst 1979; 62: 927–933
   PubMed Web of Science ®Google Scholar
• Patterson J, Strang R. The role of blood flow in hyperthermia. Int J Radiat Oncol Biol Phys 1979; 5: 235–241
   PubMed Web of Science ®Google Scholar
• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic micro-environment of human tumors: A review. Cancer Res 1989; 49: 6449–6465
   PubMed Web of Science ®Google Scholar
• Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004; 14: 198–206
   PubMed Web of Science ®Google Scholar
• Overgaard J, Bichel P. The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro. Radiol 1977; 123: 511–514
   PubMed Web of Science ®Google Scholar
• Gerweck LE, Nygaard TG, Burlett M. Response of cells to hyperthermia under acute and chronic hypoxic conditions. Cancer Res 1979; 39: 966–972
   PubMed Web of Science ®Google Scholar
• National Cancer Institute, Website: www.cancer.gov/clinicaltrials
   Google Scholar
• Patterson DM, Rustin GJS. Vascular damaging agents. Clin Oncol 2007; 19: 443–456
   PubMed Web of Science ®Google Scholar
• Thrall DE, Gillette EL, Dewey WC. Effect of heat and ionising radiation on normal and neoplastic tissue of the C3H mouse. Radiat Res 1975; 63: 363–377
   PubMed Web of Science ®Google Scholar
• Hill SA, Denekamp J. The effect of vascular occlusion on the thermal sensitization of a mouse tumor. Br J Radiol 1978; 51: 997–1002
   PubMed Web of Science ®Google Scholar
• Horsman MR, Christensen KL, Overgaard J. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int J Hyperthermia 1989; 5: 123–136
   PubMed Web of Science ®Google Scholar
• Prescott DM, Samulski TV, Dewhirst MW, Page RL, Thrall DE, Dodge RK, Oleson JR, et al. Use of nitroprusside to increase tissue temperature during local hyperthermia in normal and tumor-bearing dogs. Int J Radiat Oncol Biol Phys 1992; 23: 377–385
   PubMed Web of Science ®Google Scholar
• Urano M, Montoya V, Booth A. Effect of hyperglycemia on the thermal response of murine normal and tumor tissue. Cancer Res 1983; 43: 453–455
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in health and disease. Nature Med 2003; 9: 653–660
   PubMed Web of Science ®Google Scholar
• Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003; 9: 677–684
   PubMed Web of Science ®Google Scholar
• Moeller BJ, Cao Y, Vujaskovic Z, Li CY, Haroon ZA, Dewhirst MW. The relationship between hypoxia and angiogenesis. Sem Radiat Oncol 2004; 14: 215–221
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676
   PubMed Web of Science ®Google Scholar
• Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marmé D, Lo Russo PM, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005; 11: 416–420
   PubMed Web of Science ®Google Scholar
• Horsman MR, Siemann DW. Pathophysiological effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006; 66: 11520–11539
   PubMed Web of Science ®Google Scholar
• Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727–739
   PubMed Web of Science ®Google Scholar
• Marmé D. The impact of anti-angiogenic agents on cancer therapy. J Cancer Res Clin Oncol 2003; 129: 607–620
   PubMed Web of Science ®Google Scholar
• Eskens FALM. Angiogenesis inhibitors in clinical development: Where are we now and where are we going?. Br J Cancer 2004; 90: 1–7
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999; 80(Suppl.1)57–64
   PubMed Web of Science ®Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415–427
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chaplin DJ, Horsman MR. Vascular targeting therapies for treatment of malignant disease. Cancer 2004; 100: 2491–2499
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423–435
   PubMed Web of Science ®Google Scholar
• Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555–557
   PubMed Web of Science ®Google Scholar
• Yano T, Tanase M, Watanabe A, Sawada H, Yamada Y, Shino Y, Nakano H, Ohnishi T, et al. Enhancement effect of an anti-angiogenic agent, TNP-470, on hyperthermia-induced growth suppression of human esophageal and gastric cancers transplantable to nude mice. Anticancer Res 1995; 15: 1355–1358
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Murata R, Hiraoka M. Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia. Br J Cancer 1996; 73: 270–274
   PubMed Web of Science ®Google Scholar
• Brown PD. Matrix metalloproteinase inhibitors: A new class of anticancer agents. Curr Opin Invest Drug 1993; 2: 617–626
   Google Scholar
• Eikesdal HP, Bjorkhaug ST, Dahl O. Hyperthermia exhibits anti-vascular activity in the BT4An rat glioma: Lack of interaction with the angiogenesis inhibitor batimastat. Int J Hyperthermia 2002; 18: 141–152
   PubMed Web of Science ®Google Scholar
• Kessel D. Hematoporphyrin and HPD. Photophysics, photochemistry and phototherapy. Photochem Photobiol 1984; 39: 851–859
   PubMed Web of Science ®Google Scholar
• Dougherty TJ. Photosensitizers: Therapy and detection of malignant tumors. Photochem Photobiol 1987; 45: 879–889
   PubMed Web of Science ®Google Scholar
• Nelson JS, Wright WH, Berns MW. Histopathological comparison of the effects of hematoporphyrin derivative on two different murine tumors using computer-enhanced digital video fluorescence microscopy. Cancer Res 1985; 45: 5781–5786
   PubMed Web of Science ®Google Scholar
• Winter J. Photodynamic therapy effect in an intraocular retinoblastoma-like tumour assessed by an in vitro colony forming assay. Br J Cancer 1989; 59: 869–872
   PubMed Web of Science ®Google Scholar
• Selman SH, Kreimer-Birnbaum M, Klaunig JE, Goldblatt PJ, Keck RW, Britton SL. Blood flow in transplantable bladder tumors treated with hematoporphyrin derivative and light. Cancer Res 1984; 44: 1924–1927
   PubMed Web of Science ®Google Scholar
• Star WM, Marijnissen HPA, van den Berg-Blok AE, Versteeg JAC, Franken KAP, Reinhold HS. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res 1986; 46: 2532–2540
   PubMed Web of Science ®Google Scholar
• Horsman MR, Winther J. Vascular effects of photodynamic therapy in an intraocular retinoblastoma-like tumour. Acta Oncol 1989; 28: 693–697
   PubMed Web of Science ®Google Scholar
• Orenstein A, Kostenich G, Kopolovic Y, Babushkina T, Malik Z. Enhancement of ALA-PDT damage by IR-induced hyperthermia on a colon carcinoma model. Photochem Photobiol 1999; 69: 703–707
   PubMed Web of Science ®Google Scholar
• Kelleher DK, Bastian J, Thews O, Vaupel P. Enhanced effects of aminolaevulinic acid-based photodynamic therapy through local hyperthermia in rat tumours. Br J Cancer 2003; 89: 405–411
   PubMed Web of Science ®Google Scholar
• Kelleher DK, Thews O, Scherz A, Salomon Y, Vaupel P. Combined hyperthermia and chlorophyll-based photodynamic therapy: Tumour growth and metabolic microenvironment. Br J Cancer 2003; 89: 2333–2339
   PubMed Web of Science ®Google Scholar
• Waldow SM, Dougherty TJ. Interaction of hyperthermia and photoradiation therapy. Radiat Res 1984; 97: 380–385
   PubMed Web of Science ®Google Scholar
• Henderson BW, Waldow SM, Potter WR, Dougherty TJ. Interaction of photodynamic therapy and hyperthermia: Tumor response and cell survival studies after treatment of mice in vivo. Cancer Res 1985; 45: 6071–6077
   PubMed Web of Science ®Google Scholar
• Matsumoto N, Miyoshi N, Saito H, Fukuda M. Combination therapy of microwave hyperthermia and photodynamic therapy on squamous cell carcinoma in vivo. Hyperthermic Oncology, T Sugahara, M Saito. Taylor and Francis, London 1989; 1: 363–364
   Google Scholar
• Levendag PC, Marijnissen HPA, de Ru VJ, Versteeg JAC, van Rhoon GC, Star WM. Interaction of interstitial photodynamic therapy and interstitial hyperthermia in a rat rhabdomyosarcoma–A pilot study. Int J Radiat Oncol Biol Phys 1988; 14: 139–145
   PubMed Web of Science ®Google Scholar
• Chen Q, Chen H, Shapiro H, Hetzel F. Sequencing of combined hyperthermia and photodynamic therapy. Radiat Res 1996; 146: 293–297
   PubMed Web of Science ®Google Scholar
• Christensen T, Wahl A, Smedshammer L. Effects of haematoporphyrin derivative and light in combination with hyperthermia on cells in culture. Br J Cancer 1984; 50: 85–89
   PubMed Web of Science ®Google Scholar
• Mang TS, Dougherty TJ. Time and sequence dependent influence of in vitro photodynamic therapy (PDT) survival by hyperthermia. Photochem Photobiol 1985; 42: 533–540
   PubMed Web of Science ®Google Scholar
• Horsman MR, Chaplin DJ, Overgaard J. The effect of combining flavone acetic acid and hyperthermia on the growth of a C3H mammary carcinoma. Int J Radiat Biol 1991; 60: 385–388
   PubMed Web of Science ®Google Scholar
• Sakaguchi Y, Maehara Y, Baba H, Kusumoto T, Sugimachi K, Newman RA. Flavone acetic acid increases the antitumor effect of hyperthermia in mice. Cancer Res 1992; 52: 3306–3309
   PubMed Web of Science ®Google Scholar
• Horsman MR, Sampson LE, Chaplin DJ, Overgaard J. The in vivo interaction between flavone acetic acid and hyperthermia. Int J Hyperthermia 1996; 12: 779–789
   PubMed Web of Science ®Google Scholar
• Eikesdal HP, Schem BC, Mella O, Dahl O. The new tubulin inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. Int J Radiat Oncol Biol Phys 2000; 46: 645–652
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Lee SH, Rood KL, Stewart MJ, Lyons JC, Lew YS, Park H, Song CW, et al. Use of arsenic trioxide as an antivascular and thermosensitising agent in solid tumors. Neoplasia 2000; 2: 555–560
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Potentiation of the anti-tumor effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2001; 17: 508–519
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 2001; 51: 1018–1024
   PubMed Web of Science ®Google Scholar
• Eikesdal HP, Bjerkvig R, Mella O, Dahl O. Combretastatin A-4 and hyperthermia: A patent combination for the treatment of solid tumors. Radiother Oncol 2001; 60: 147–154
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Monzen H, Williams BW, Park H, Lee SH, Song CW. Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hyperthermia 2003; 19: 575–589
   PubMed Web of Science ®Google Scholar
• Kallinowski F, Moehle R, Vaupel P. Substantial enhancement of tumor hyperthermic response by tumor necrosis factor. Hyperthermic Oncology, T Sugahara, M Saito. Taylor and Francis, London 1989; 1: 258–259
   Google Scholar
• Lin JC, Park HJ, Song CW. Combined treatment of IL-α and TNF-α potentiates the antitumour effect of hyperthermia. Int J Hyperthermia 1996; 12: 335–344
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Prescott DM, Clegg S, Samulski TV, Page RL, Thrall DE, Leopold K, Rosner G, Acker JC, Oleson JR, et al. The use of hydralazine to manipulate tumour temperatures during hyperthermia. Int J Hyperthermia 1990; 6: 971–983
   PubMed Web of Science ®Google Scholar
• Honess DJ, Hu DE, Bleehen NM. A study of the mechanism of hydralazine enhancement of thermal damage in the KHT tumour. Int J Hyperthermia 1991; 7: 667–679
   PubMed Web of Science ®Google Scholar
• Kalmus J, Okunieff P, Vaupel P. Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSaII tumors. Cancer Res 1990; 50: 15–19
   PubMed Web of Science ®Google Scholar
• Eikesdal HP, Bjerkvig R, Dahl O. Vnblastine and hyperthermia target the neovasculature in BT4AN rat gliomas: Therapeutic implications of the vascular phenotype. Int J Radiat Oncol Biol Phys 2001; 51: 535–544
   PubMed Web of Science ®Google Scholar
• Breidahl T, Nielsen FU, Stødkilde-Jørgensen H, Maxwell RJ, Horsman MR. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: A comparative assessment using MRI and MRS. Acta Oncol 2006; 1998; 45: 306–316
   Google Scholar
• Horsman MR, Murata R. Vascular targeting therapies and hyperthermia. Vascular-targeted therapies in oncology, DW Siemann. John Wiley and Sons, London 2006; 137–157
   Google Scholar
• Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001; 77: 195–204
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol 2001; 40: 497–503
   PubMed Web of Science ®Google Scholar
• Dereski M, Madigan L, Chopp M. The effect of hypothermia and hyperthermia on photodynamic therapy of normal brain: Experimental study. Neurosurgery 1995; 36: 141–146
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents. Br J Cancer 1996; 74(Suppl.XXVII)S86–S88
   PubMedGoogle Scholar
• Overgaard J. Rationale and problems in the design of clinical trials. Hyperthermic oncology, J Overgaard. Taylor and Francis, London 1985; 2: 325–338
   Google Scholar
• Horsman MR, Overgaard J. Hyperthermia: A potent enhancer of radiotherapy. Clin Oncol 2007; 19: 418–426
   PubMed Web of Science ®Google Scholar
• Murata R, Horsman MR. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2004; 20: 393–404
   PubMed Web of Science ®Google Scholar